← Russell 3000 cross-section

TLSI TriSalus Life Sciences, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$311m
Revenue TTM
$45m
Net income TTM
$-28m
Free cash flow
$-23m
Composite score
Sector rank
#2638

Valuation

P / E
EV / EBITDA
EV / sales
6.6
FCF yield
-7.49%
Earnings yield vs 10-yr
-13.80pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-62.6%
EBITDA margin
ROE
-430.7%
ROIC
Revenue growth
25.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our current pricing allows us to generate a substantial gross margin, which provides funds to support our growth and our research and development (“R&D”) for both TriNav and nelitolimod. Revenue We currently operate in one reportable segment and revenue is generated primarily from sales of PEDD infusion systems to our customers, principally related to TriNav. Sales and Marketing Sales and marketing expense consists primarily of salaries, commissions, travel and related business expenses for our sales force, which is principally engaged in physician education regarding the features and benefits of TriNav. …TriSalus Life Sciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →